IPH Share Price

Open 13.43 Change Price %
High 13.51 1 Day -0.08 -0.60
Low 13.22 1 Week -0.30 -2.20
Close 13.36 1 Month 2.25 20.25
Volume 155939 1 Year -0.36 -2.62
52 Week High 14.97
52 Week Low 8.26
IPH Important Levels
Resistance 2 13.63
Resistance 1 13.52
Pivot 13.36
Support 1 13.20
Support 2 13.09
EPA France Most Active Stocks
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
MT 4.53 12.97%
SOI 1.25 15.74%
SOI 1.25 15.74%
SOI 1.25 15.74%
DPT 0.21 -22.22%
ALEUP 0.26 -3.70%
More..
EPA France Top Gainers Stocks
AVT 0.06 20.00%
AVT 0.06 20.00%
AVT 0.06 20.00%
AVT 0.06 20.00%
TONN 1.10 15.79%
SOI 1.25 15.74%
SOI 1.25 15.74%
SOI 1.25 15.74%
APAM 33.78 15.72%
APAM 33.78 15.72%
More..
EPA France Top Losers Stocks
LTAN 1.94 -34.46%
ALALO 0.03 -25.00%
DPT 0.21 -22.22%
MLGES 1.52 -22.05%
ALADO 0.04 -20.00%
MLVER 6.81 -11.56%
MLTRO 3.41 -11.43%
ALFRE 1.10 -9.84%
ALSAS 5.44 -9.33%
OXI 0.16 -5.88%
More..

Innate Pharma SA (EPA: IPH)

IPH Technical Analysis 3
As on 8th Dec 2016 IPH Share Price closed @ 13.36 and we RECOMMEND Buy for LONG-TERM with Stoploss of 11.67 & Buy for SHORT-TERM with Stoploss of 12.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPH Target for December
1st Target up-side 16.63
2nd Target up-side 18.33
3rd Target up-side 20.04
1st Target down-side 11.75
2nd Target down-side 10.05
3rd Target down-side 8.34
IPH Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.innate-pharma.com
IPH Address
IPH
117, Avenue de Luminy
Marseille, 13009
France
Phone: 33 4 30 30 30 30
Fax: 33 4 30 30 30 00
Interactive Technical Analysis Chart Innate Pharma SA ( IPH EPA France )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Innate Pharma SA
IPH Business Profile
Innate Pharma S.A., a biopharmaceutical company, engages in the development of immunotherapy drug candidates for cancer and inflammatory diseases. The company primarily develops monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its product candidates in clinical development comprise Lirilumab (IPH2102/BMS-986015), a monoclonal antibody (IgG4) blocking killer-cell immunoglobulin-like receptors (KIR) in Phase II trials for acute myeloid leukemia and two Phase I clinical trials to solid tumors in combination with ipilimumab and nivolumab respectively; and IPH2201/NN8765, an anti-NKG2A antibody in Phase I clinical trials for the treatment of inflammatory conditions and autoimmune diseases, and in rheumatoid arthritis. The company’s pre-clinical product candidates include IPH41, a cytotoxic mAb that targets KIR3DL2, an inhibitory receptor of NK cells; and IPH33, a blocking mAb targeting TLR3, an inducer of Type I IFN and pro-inflammatory cytokines. It has licensing agreements with Bristol-Myers Squibb for the development of IPH2102; and Novo Nordisk A/S for the development of IPH2201. Innate Pharma S.A. was founded in 1999 and is headquartered in Marseilles, France.